Effects of the protein corona on liposome-liposome and liposome-cell interactions

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3049-3063

  Corbo, Claudia ^a,b   Molinaro, Roberto ^a   Taraballi, Francesca ^a   Toledano Furman, Naama E ^a   Sherman, Michael B ^c   Parodi, Alessandro ^a   Salvatore, Francesco ^b,d   Tasciotti, Ennio ^a,e  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Cancer cells; Liposomes; Macrophages; Protein corona

Indexed keywords

LIPOSOME; NANOPARTICLE; PROTEIN CORONA; PLASMA PROTEIN;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; INTERNALIZATION; LIPOSOME CELL INTERACTION; LIPOSOME LIPOSOME INTERACTION; MACROPHAGE; MATERIAL COATING; MOLECULAR INTERACTION; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SURFACE CHARGE; TUMOR CELL; ULTRASTRUCTURE; YOUNG MODULUS; ZETA POTENTIAL; ANIMAL; ATOMIC FORCE MICROSCOPY; BAGG ALBINO MOUSE; CELL COMMUNICATION; CHEMISTRY; CRYOELECTRON MICROSCOPY; ENDOCYTOSIS; HUMAN; METABOLISM; PHOTON CORRELATION SPECTROSCOPY; PROTEOMICS; TUMOR CELL LINE;

ADSORPTION; ANIMALS; BLOOD PROTEINS; CELL COMMUNICATION; CELL LINE, TUMOR; CRYOELECTRON MICROSCOPY; DYNAMIC LIGHT SCATTERING; ENDOCYTOSIS; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MICE, INBRED BALB C; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PROTEIN CORONA; PROTEOMICS;

EID: 84979701306     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S109059     Document Type: Article

References (52)

1. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215-223.
2. Lundqvist M. Nanoparticles: tracking protein corona over time. Nat Nanotechnol. 2013;8(10):701-702.
3. Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772-781.
4. Lynch I, Dawson KA. Protein-nanoparticle interactions. Nano Today. 2008;3(1):40-47.
5. Mirsadeghi S, Dinarvand R, Ghahremani MH, et al. Protein corona composition of gold nanoparticles/nanorods affects amyloid beta fibrillation process. Nanoscale. 2015;7(11):5004-5013.
6. O’Connell D, Bombelli FB, Pitek A, Monopoli M, Cahill D, Dawson KA. Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials. Nanoscale. 2015;7(37): 15268-15276.
7. Zanganeh S, Spitler R, Erfanzadeh M, Alkilany AM, Mahmoudi M. Protein corona: opportunities and challenges. Int J Biochem Cell Biol. 2016;75:143-147.
8. Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine. 2016;11(1): 81-100.
9. Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137-143.
10. Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraft ML. Protein corona significantly reduces active targeting yield. Chem Commun (Camb). 2013;49(25):2557-2559.
11. Qiu Y, Liu Y, Wang L, et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials. 2010;31(30): 7606-7619.
12. Ge C, Du J, Zhao L, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A. 2011;108(41): 16968-16973.
13. Ge C, Tian J, Zhao Y, Chen C, Zhou R, Chai Z. Towards understanding of nanoparticle-protein corona. Arch Toxicol. 2015;89(4): 519-539.
14. Sahneh FD, Scoglio CM, Monteiro-Riviere NA, Riviere JE. Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling. Nanomedicine (Lond). 2015;10(1):25-33.
15. Milani S, Baldelli Bombelli F, Pitek AS, Dawson KA, Radler J. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano. 2012;6(3):2532-2541.
16. Liu W, Rose J, Plantevin S, Auffan M, Bottero J-Y, Vidaud C. Protein corona formation for nanomaterials and proteins of a similar size: hard or soft corona? Nanoscale. 2013;5(4):1658-1668.
17. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011;8(3):343-357.
18. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-478.
19. Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft ML. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials. 2016;75:295-304.
20. Caracciolo G, Palchetti S, Colapicchioni V, et al. Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. Langmuir. 2015;31(39):10764-10773.
21. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657-3666.
22. Kulkarni SA, Feng S-S. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res. 2013;30(10):2512-2522.
23. Caracciolo G. The protein corona effect for targeted drug delivery. Bioinspired Biomimetic Nanobiomater. 2013;2(1):54-57.
24. Mahon E, Salvati A, Bombelli FB, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for “targeting and therapeutic delivery”. J Control Release. 2012;161(2):164-174.
25. Van Rooijen N, van Nieuwmegen R. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol Commun. 1980;9(3):243-256.
26. Lee H, Blaufox M. Blood volume in the rat. J Nucl Med. 1985;26(1): 72-76.
27. Monopoli MP, Walczyk D, Campbell A, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc. 2011;133(8):2525-2534.
28. Maugis D. Contact, Adhesion and Rupture of Elastic Solids. Vol. 130. Berlin: Springer Science & Business Media; 2013.
29. Corbo C, Orrù S, Gemei M, et al. Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. Proteomics. 2012;12(12):2045-2059.
30. Caterino M, Corbo C, Imperlini E, et al. Differential proteomic analysis in human cells subjected to ribosomal stress. Proteomics. 2013; 13(7):1220-1227.
31. Corbo C, Parodi A, Evangelopoulos M, et al. Proteomic profiling of a biomimetic drug delivery platform. Curr Drug Targets. 2015;16(13): 1540-1547.
32. Li G-Z, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics. 2009;9(6):1696-1719.
33. Nuutila J, Lilius EM. Flow cytometric quantitative determination of ingestion by phagocytes needs the distinguishing of overlapping populations of binding and ingesting cells. Cytometry A. 2005;65(2): 93-102.
34. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell “sees” in bionanoscience. J Am Chem Soc. 2010;132(16): 5761-5768.
35. Barrán-Berdón AL, Pozzi D, Caracciolo G, et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir. 2013;29(21):6485-6494.
36. Wolfram J, Suri K, Yang Y, et al. Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces. 2014;114: 294-300.
37. Hadjidemetriou M, Al-Ahmady Z, Mazza M, Collins RF, Dawson K, Kostarelos K. In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles. ACS Nano. 2015;9(8):8142-8156.
38. Miclaus T, Bochenkov VE, Ogaki R, Howard KA, Sutherland DS. Spatial mapping and quantification of soft and hard protein coronas at silver nanocubes. Nano Lett. 2014;14(4):2086-2093.
39. Gräfe C, Weidner A, vd Lühe M, et al. Intentional formation of a protein corona on nanoparticles-serum concentration affects protein corona mass, surface charge, and nanoparticle-cell interaction. Int J Biochem Cell Biol. 2016;75:196-202.
40. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.
41. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev. 2011;111(9):5610-5637.
42. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012;41(7):2780-2799.
43. Tenzer S, Docter D, Rosfa S, et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano. 2011;5(9): 7155-7167.
44. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008;105(38):14265-14270.
45. Yan Y, Gause KT, Kamphuis MM, et al. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. 2013;7(12): 10960-10970.
46. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010;398(1-2):190-203.
47. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010; 11(9):785-797.
48. Johnson WJ, Mahlberg FH, Rothblat GH, Phillips MC. Cholesterol transport between cells and high-density lipoproteins. Biochim Biophys Acta. 1991;1085(3):273-298.
49. Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004;64(4):1515-1521.
50. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271(5248):518-520.
51. Palchetti S, Colapicchioni V, Digiacomo L, et al. The protein corona of circulating PEGylated liposomes. Biochim Biophys Acta. 2016; 1858(2):189-196.
52. Pozzi D, Caracciolo G, Digiacomo L, et al. The biomolecular corona of nanoparticles in circulating biological media. Nanoscale. 2015; 7(33):13958-13966.